EMA401

Ligand id: 8374

Name: EMA401

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 76.07
Molecular weight 507.2
XLogP 9.83
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

References
1. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG. (2008)
Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system.
Endocrinology149 (7): 3452-60. [PMID:18388195]
2. Finnerup NB, Baastrup C. (2014)
Angiotensin II: from blood pressure to pain control.
Lancet383 (9929): 1613-4. [PMID:24507378]
3. McCarthy T. (2014)
Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.
J. Peripher. Nerv. Syst.19 Suppl 2: S13-4. [PMID:25269730]
4. Patil J, Schwab A, Nussberger J, Schaffner T, Saavedra JM, Imboden H. (2010)
Intraneuronal angiotensinergic system in rat and human dorsal root ganglia.
Regul. Pept.162 (1-3): 90-8. [PMID:20346377]
5. Rice AS, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N et al.. (2014)
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Lancet383 (9929): 1637-47. [PMID:24507377]
6. Smith MT. (2013)
Method of treatment or prophylaxis of inflammatory pain.
Patent number: US8551950. Assignee: Spinifex Pharmaceuticals Pty Ltd. Priority date: 20/03/2006. Publication date: 08/10/2013.
7. Smith MT, Wyse BD. (2010)
Method of treatment or prophylaxis.
Patent number: US7795275. Assignee: Uniquest Pty Limited. Priority date: 24/12/2004. Publication date: 14/09/2010.
8. Smith MT, Wyse BD, Edwards SR. (2013)
Small molecule angiotensin II type 2 receptor (ATâ‚‚R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.
Pain Med14 (5): 692-705. [PMID:23489258]